[go: up one dir, main page]

RU2003113322A - ERYTHROMYCIN DERIVATIVE HAVING NEW CRYSTAL STRUCTURES AND METHODS FOR PRODUCING THERE - Google Patents

ERYTHROMYCIN DERIVATIVE HAVING NEW CRYSTAL STRUCTURES AND METHODS FOR PRODUCING THERE

Info

Publication number
RU2003113322A
RU2003113322A RU2003113322/04A RU2003113322A RU2003113322A RU 2003113322 A RU2003113322 A RU 2003113322A RU 2003113322/04 A RU2003113322/04 A RU 2003113322/04A RU 2003113322 A RU2003113322 A RU 2003113322A RU 2003113322 A RU2003113322 A RU 2003113322A
Authority
RU
Russia
Prior art keywords
crystalline form
fumarate salt
compound
ppm
formula
Prior art date
Application number
RU2003113322/04A
Other languages
Russian (ru)
Other versions
RU2264408C2 (en
Inventor
Акира ХИРАИДЕ
Кантиро КОЯМА
Хитоси СИМИЗУ
Канаме ЦУЗАКИ
Original Assignee
Чугаи Сейяку Кабусики Кайся
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Чугаи Сейяку Кабусики Кайся filed Critical Чугаи Сейяку Кабусики Кайся
Publication of RU2003113322A publication Critical patent/RU2003113322A/en
Application granted granted Critical
Publication of RU2264408C2 publication Critical patent/RU2264408C2/en

Links

Claims (14)

1. Кристаллическая форма Е фумаратной соли соединения, представленного формулой (I)1. The crystalline form E of the fumarate salt of the compound represented by formula (I)
Figure 00000001
Figure 00000001
 где указанная кристаллическая форма Е имеет сильные рентгеновские дифракционные пики при углах дифракции (2θ) 5,6° и 10,4°, как установлено с помощью рентгеновской дифрактометрией с Cu-Kα-излучением.where the specified crystalline form E has strong x-ray diffraction peaks at diffraction angles (2θ) of 5.6 ° and 10.4 °, as established by x-ray diffractometry with Cu-Kα radiation. 2. Способ получения кристаллической формы Е фумаратной соли соединения, представленного формулой (I)2. A method of obtaining a crystalline form E of a fumarate salt of the compound represented by formula (I)
Figure 00000002
Figure 00000002
 который включает обработку кристаллической формы С фумаратной соли соединения (I) в смешанном растворителе из этилацетата и воды при 20-40°С, где указанная кристаллическая форма Е имеет сильные рентгеновские дифракционные пики при углах дифракции (2θ) 5,6° и 10,4°, как установлено с помощью рентгеновской дифрактометрией с Cu-Kα-излучением.which comprises treating the crystalline form C of the fumarate salt of compound (I) in a mixed solvent of ethyl acetate and water at 20-40 ° C, where said crystalline form E has strong X-ray diffraction peaks at diffraction angles (2θ) of 5.6 ° and 10.4 °, as determined by x-ray diffractometry with Cu-Kα radiation. 3. Кристаллическая форма D фумаратной соли соединения, представленного формулой (I)3. The crystalline form D of the fumarate salt of the compound represented by formula (I)
Figure 00000003
Figure 00000003
 полученная через кристаллическую форму Е фумаратной соли соединения (I), имеющую сильные рентгеновские дифракционные пики при углах дифракции (2θ) 5,6° и 10,4°, как установлено с помощью рентгеновской дифрактометрией с Cu-Kα-излучением.obtained through the crystalline form E of the fumarate salt of compound (I) having strong X-ray diffraction peaks at diffraction angles (2θ) of 5.6 ° and 10.4 °, as established by X-ray diffractometry with Cu-Kα radiation. 4. Кристаллическая форма D по п.3, где содержание остаточного растворителя составляет 1500 ч./млн или менее.4. Crystalline form D according to claim 3, where the content of residual solvent is 1500 ppm or less. 5. Кристаллическая форма D по п.3, где содержание остаточного растворителя составляет 1000 ч./млн или менее.5. Crystalline form D according to claim 3, where the content of residual solvent is 1000 ppm or less. 6. Соединение по любому из пп.3-5, где средний размер частиц составляет 90 мкм или более.6. The compound according to any one of claims 3 to 5, where the average particle size is 90 microns or more. 7. Соединение по любому из пп.3-5, где средний размер частиц составляет 100 мкм или более.7. The compound according to any one of claims 3 to 5, where the average particle size is 100 μm or more. 8. Способ получения кристаллической формы D фумаратной соли соединения, представленного формулой (I)8. The method of obtaining crystalline form D of the fumarate salt of the compounds represented by formula (I)
Figure 00000004
Figure 00000004
 который включает получение кристаллической формы D через кристаллическую форму Е фумаратной соли соединения (I), имеющую сильные рентгеновские дифракционные пики при углах дифракции (2θ) 5,6° и 10,4°, как установлено с помощью рентгеновской дифрактометрией с Cu-Kα-излучением.which involves obtaining crystalline form D through crystalline form E of the fumarate salt of compound (I) having strong X-ray diffraction peaks at diffraction angles (2θ) of 5.6 ° and 10.4 °, as determined by Cu-Kα radiation X-ray diffractometry . 9. Способ по п.8, где содержание остаточного растворителя в кристаллической форме D фумаратной соли соединения (I) составляет 1500 ч./млн или менее.9. The method of claim 8, where the residual solvent in crystalline form D of the fumarate salt of compound (I) is 1500 ppm or less. 10. Способ по п.8, где содержание остаточного растворителя в кристаллической форме D фумаратной соли соединения (I) составляет 1000 ч./млн или менее.10. The method of claim 8, where the residual solvent in crystalline form D of the fumarate salt of compound (I) is 1000 ppm or less. 11. Способ по любому из пп.8-10, где средний размер частиц в кристаллической форме D фумаратной соли соединения (I) составляет 90 мкм или более.11. The method according to any one of claims 8 to 10, where the average particle size in crystalline form D of the fumarate salt of compound (I) is 90 μm or more. 12. Способ по любому из пп.8-10, где средний размер частиц в кристаллической форме D фумаратной соли соединения (I) составляет 100 мкм или более.12. The method according to any one of claims 8 to 10, where the average particle size in crystalline form D of the fumarate salt of compound (I) is 100 μm or more. 13. Кристаллическая форма D фумаратной соли соединения, представленного формулой (I):13. Crystalline form D of the fumarate salt of the compound represented by formula (I):
Figure 00000005
Figure 00000005
 где содержание остаточного растворителя составляет 1500 ч./млн или менее.where the residual solvent content is 1500 ppm or less. 14. Кристаллическая форма D фумаратной соли соединения, представленного формулой (I)14. Crystalline form D of the fumarate salt of the compound represented by formula (I)
Figure 00000006
Figure 00000006
 где содержание остаточного растворителя составляет 1000 ч./млн или менее.where the residual solvent content is 1000 ppm or less.
RU2003113322/04A 2000-10-12 2001-10-12 Erythromycin derivative of novel crystalline structures and methods for their preparing RU2264408C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000312220 2000-10-12
JP2000-312220 2000-10-12

Publications (2)

Publication Number Publication Date
RU2003113322A true RU2003113322A (en) 2004-12-10
RU2264408C2 RU2264408C2 (en) 2005-11-20

Family

ID=18791856

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2003113322/04A RU2264408C2 (en) 2000-10-12 2001-10-12 Erythromycin derivative of novel crystalline structures and methods for their preparing

Country Status (10)

Country Link
US (1) US7645864B2 (en)
EP (1) EP1334726A4 (en)
JP (2) JP4275407B2 (en)
KR (1) KR100540021B1 (en)
CN (1) CN1231490C (en)
AU (2) AU9424401A (en)
CA (1) CA2425913C (en)
RU (1) RU2264408C2 (en)
TW (1) TWI286139B (en)
WO (1) WO2002030943A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7384921B2 (en) * 2004-02-20 2008-06-10 Enanta Pharmaceuticals, Inc. Polymorphic forms of 6-11 bicyclic ketolide derivatives
CA2629227C (en) 2005-11-29 2014-02-25 Nihon Medi-Physics Co., Ltd. Precursor compound of radioactive halogen-labeled organic compound
US9273208B2 (en) * 2011-02-21 2016-03-01 Kaneka Corporation Acrylic resin film
CN102212094B (en) * 2011-03-14 2013-08-21 金泳霖 Processing process of erythromycin residual decoction dregs
CN102911226B (en) * 2011-08-03 2015-11-25 胡梨芳 Erythromycin octadecanoate compounds thing entity and uses thereof
CN113636571B (en) 2020-05-11 2022-11-01 中国石油化工股份有限公司 SCM-33 molecular sieve and preparation method and application thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY113693A (en) 1992-05-26 2002-05-31 Chugai Pharmaceutical Co Ltd Erythromycin derivatives having an enterokinesis stimulating action
ZA966601B (en) 1995-08-03 1997-02-19 Chugai Pharmaceutical Co Ltd Process for producing erythromycin derivatives.
SE9802974D0 (en) * 1998-09-03 1998-09-03 Astra Ab New crystalline forms

Similar Documents

Publication Publication Date Title
Featherstone et al. Synthetic apatites containing Na, Mg, and CO3 and their comparison with tooth enamel mineral
Gangu et al. Novel iron doped calcium oxalates as promising heterogeneous catalysts for one-pot multi-component synthesis of pyranopyrazoles
RU2006127044A (en) CRYSTAL FORM OF CHINOLINE COMPOUND AND METHOD FOR PRODUCING THIS COMPOUND IN THE SPECIFIED FORM
RU2734633C1 (en) Quaternary ammonium cation based on morpholinium and obtained using zeolite of aei type
RU2014126869A (en) WATER GAS CONVERSION CATALYST, FUNCTIONING AT AVERAGE TEMPERATURE, AND METHOD OF PRODUCING IT
EA200300103A1 (en) NEW β CRYSTAL FORM OF TREAT-BUTYLAMINE SALT PERINDOPRIL, METHOD FOR ITS PREPARATION AND CONTAINING ITS PHARMACEUTICAL COMPOSITIONS
Han et al. Hydrothermal crystal growth and characterization of cerium hydroxycarbonates
RU2003113322A (en) ERYTHROMYCIN DERIVATIVE HAVING NEW CRYSTAL STRUCTURES AND METHODS FOR PRODUCING THERE
Piccione et al. A new structure-directing agent for the synthesis of pure-phase ZSM-11
JP2006507337A5 (en)
TR200003749A3 (en) Steam cracking reactions catalyst and catalyst preparation process
EA200000654A1 (en) HYDRATE OF SALT OF MALEIC ACID 5- [4- [2- (N-METHYL-N- (2-Pyridyl) AMINO) ETOXY] BENZYL] -THIAZOLIDIN-2,4-DIONA AS A PHARMACEUTICAL PREPARATION
Sekar et al. Effect of KCl addition on crystal growth and spectral properties of glycine single crystals
Ke et al. Construction of direct Z-scheme WO3 (H2O) 0.333/BiOI heterostructure with enhanced visible light photocatalytic performance
RU97112145A (en) GETTING CEFOTAXIM
CA2516643A1 (en) Method for preparing polymorphism of irinotecan hydrochloride
CN105419785B (en) Multi-photon polarization laser material being combined based on metal organic frame host and guest build and preparation method thereof
Sunkara et al. Hantzsch synthesis of 1, 4-dihydropyridine derivatives over ZnO/ZrO2 catalyst under solvent free condition
Han et al. Hydroxide carbonates and oxide carbonate hydrate of rare earths grown on glass via a hydrothermal route
Martins et al. Physical transformations of the active pharmaceutical ingredient BN83495: enantiotropic and monotropic relationships. Access to several polymorphic forms by using various solvation–desolvation processes
RU99120777A (en) BASIC MAGNESIUM ALUMINUM CARBONATE, METHOD FOR ITS PRODUCTION, PHARMACEUTICAL COMPOSITION ON ITS BASIS AND METHOD FOR TREATING AN INCREASED GASTRIC ACIDITY
RU2547739C1 (en) Method of growing mixed cobalt-nickel-potassium sulphate crystals for ultraviolet range optical filters
RU2632437C1 (en) Method of producng aluminium oxide
EP1323701A4 (en) Methods for crystallization of hydroxycarboxylic acids
RU2000121112A (en) METAL DERIVATIVES OF ARABINOGALACTAN, METHOD FOR PRODUCING METAL DERIVATIVES OF ARABINOGALACTAN